BGB-283

Ligand id: 8958

Name: BGB-283

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 89.13
Molecular weight 478.13
XLogP 4.73
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
5-[[(1R,1aS,6bR)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
Synonyms
compound 2.2b [2]
Database Links
PubChem CID 89670174
RCSB PDB Ligand 3K3
Search Google for chemical match using the InChIKey NGFFVZQXSRKHBM-FKBYEOEOSA-N
Search Google for chemicals with the same backbone NGFFVZQXSRKHBM
Search UniChem for chemical match using the InChIKey NGFFVZQXSRKHBM-FKBYEOEOSA-N
Search UniChem for chemicals with the same backbone NGFFVZQXSRKHBM
SynPHARM 83246 (in complex with B-Raf proto-oncogene, serine/threonine kinase)
Comments
BGB-283 is an investigational inhibitor of the Raf kinases (ARAF, BRAF, CRAF) and the epidermal growth factor receptor (EGFR) tyrosine kinase [1]. BGB-283 is being investigated for its antineoplastic activity. The compound is one of the structures described in patent WO2013097224 A1 [2].